

# Pneumonia Therapeutics Global Market Report 2025: An Analysis of Market Growth, Trends and Key Players

*The Business Research Company's  
Pneumonia Therapeutics Global Market  
Report 2025 – Market Size, Trends, And  
Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, March 27, 2025

[/Einpresswire.com/](https://www.einpresswire.com/) -- What are the  
Projected Market Dynamics for  
Pneumonia Therapeutics?

The pneumonia therapeutics market size has burgeoned swiftly in recent years, growing from \$10.35 billion in 2024 to an estimated \$11.49 billion in 2025, presenting a compound annual growth rate CAGR of 11.0%. This historic period growth can be linked to several factors, including the increase in prevalence of drug-resistant strains, rise in awareness of pneumonia prevention, growth in elderly and immunocompromised populations, expanded vaccination programs, and improved healthcare infrastructure.



Get 20% off on Global  
Market Reports until March  
31st! Use code FY25SAVE at  
checkout.”

*The Business Research  
Company*

The market is forecasted to witness rapid growth, escalating to a whopping \$17.26 billion by the year 2029, demonstrating a CAGR of 10.7%. This future growth is projected to be largely driven by increasing antibiotic-

resistant strains, growing prevalence of pneumonia in aging populations, the expanding role of telemedicine for early diagnosis, rising healthcare expenditures in emerging markets, increasing funding for infectious disease research, and heightened awareness campaigns.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21258&type=smp>

What Drives the Phenomenal Development of the Pneumonia Therapeutics Market?

The escalating prevalence of pneumonia is primed to significantly propel the growth of the pneumonia therapeutics market. Pneumonia, a lung infection that inflames the air sacs, often



The Business  
Research Company

The Business Research Company

triggers symptoms such as cough, fever, and difficulty breathing. The surge in pneumonia cases is typically associated with ageing populations, air pollution, smoking, compromised immune systems, antimicrobial resistance, and the spread of respiratory infections like COVID-19 or influenza. Pneumonia therapeutics play a critical role in combating the infection's cause, such as bacteria, viruses, or fungi, employing targeted medications while supporting health recovery through oxygen therapy, anti-inflammatory drugs, and symptom management.

In 2023, according to the National Center for Biotechnology Information, a US-based government agency, pneumonia decimated approximately 120 million people annually, causing roughly 1.3 million deaths globally. A shocking 80% of pediatric pneumonia-inflicted deaths were reported in children under 2 in developing countries. The intensifying prevalence of pneumonia substantiates the growth of the pneumonia therapeutics market.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/pneumonia-therapeutics-global-market-report>

Who are the Significant Players Contributing to the Growth of the Pneumonia Therapeutics Market?

The pneumonia therapeutics market is energized by several leading companies such as Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., and Tergene Biotech Limited.

Do Any Emerging Trends Impact the Size of the Pneumonia Therapeutics Market?

In an effort to maintain a competitive edge in the industry, top-tier companies in the pneumonia therapeutics market are continuously honing their strategies to develop innovative drug formulations and therapeutic methods such as antibiotic drugs. For instance, in June 2024, a collaboration between India-based pharmaceutical companies, Orchid Pharma Limited and Cipla Limited, led to the introduction of cefepime-enmetazobactam, an antibiotic combination designed to treat complex infections, such as UTIs and pneumonia. This innovative solution targets pneumonia strains resistant to conventional medicines and minimizes the need for potent antibiotics while ensuring effective treatment.

How is the Pneumonia Therapeutics Market Segmented?

1 Product: Drugs, Vaccine, Oxygen Therapy

2 Infection: Hospital-Acquired Pneumonia HAP, Community-Acquired Pneumonia CAP, Ventilator-Associated Pneumonia VAP

3 Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4 End Use: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments are divided into Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, Other Drugs, Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B Hib Vaccines, Influenza Vaccines, Other Vaccines, and Oxygen Therapy: High-Flow Nasal Cannula HFNC, Non-Invasive Ventilation NIV, Mechanical Ventilation, Other Oxygen Therapies.

What is the Regional Outlook for the Pneumonia Therapeutics Market?

North America dominated the pneumonia therapeutics market in 2024 and is poised to be outpaced by Asia-Pacific, expected to be the fastest-growing region in the forecasted period. The report envelops key regions worldwide including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse For More Similar Reports-

Anti-Asthmatics And COPD Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report>

Asthma Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report>

Myasthenia Gravis Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report>

At The Business Research Company, we take pride in providing insightful data-rich research with over 15000+ reports from 27 industries spanning 60+ geographies. Our distinct blend of 1,500,000 datasets, in-depth secondary research, and comprehensive insights from industry leaders, helps you navigate the competitive business landscape.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/797596427>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.